Novavax is a biotechnology company focused on protein-based vaccines built on a nanoparticle platform and Matrix-M adjuvant. It is best known for its COVID-19 vaccine (marketed as Nuvaxovid/Covovax in various regions) and works on additional infectious-disease programs. Unlike mRNA vaccine makers, its approach uses recombinant proteins designed to present antigens in a virus-like particle format to the immune system.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 239.2 | — | 106.5 | -27% |
| Q3 2025 | 70.4 | — | -202.4 | — |
| Q4 2025 | 147.1 | — | 17.5 | — |
| Q1 2026 | 139.5 | — | -9.5 | -102% |
| Q2 2026 | 56.7 | -76.3% | -53.4 | -150.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cimpress plc (CMPR), LeMaitre Vascular, Inc. (LMAT), Amplitude, Inc. (AMPL), Diversified Healthcare Trust (DHC), Allegiant Travel Company (ALGT), Astrana Health, Inc. (ASTH)